European Psychiatry - Volume 41 - April 2017

274 / 916

S270 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302
been accepted as a valuable outcome measure in many psychiatric
conditions; thus, identification of contributing factors may help to
improve overall outcome. Moreover, close monitoring of adverse
effects of illness on QoL in healthy siblings may become a part of
larger prevention strategies.
Supported by the grant projects MH CR AZV 15-28998A, MEYS
NPU4NUDZ: LO1611.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
Reference
[1] Bowman S, Alvarez-Jimenez M, Wade D, Howie L, McGorry P.
The impact of first episode psychosis on sibling quality of life.
Soc Psychiatry Psychiatr Epidemiol 2014;49:1071–81.
EW0481
Diagnosis of predominant negative
symptoms: Post-hoc analyses of a
phase 3 clinical trial with cariprazine
monotherapy and risperidone
I. Laszlovszky ∗, Á. Barabássy , E. Szalai , B. Szatmári , J. Harsányi ,
G. Németh
Gedeon Richter Plc, Medical Division, Budapest, Hungary
∗ Corresponding author.
Objective To present, post hoc analyses from a controlled,
prospective study of predominant negative symptoms (PNS) of
schizophrenia on baseline patient characteristics, severity of symp-
toms and their variability among participating countries.
Methods Data were analyzed from a phase 3, randomized,
double-blind, active-controlled, parallel-group study in adult PNS
patients with schizophrenia (EudraCT Number 2012-005485-36).
Subjects with a PANSS factor score for negative symptoms (PANSS-
FSNS) ≥ 24 and no pseudo-specific factors (e.g. high positive
symptoms, extrapyramidal symptoms, depression) were random-
ized to cariprazine 4.5mg/d (dose range: 3–6mg/d) or risperidone
4mg/d (dose range: 3–6mg/d) for 26 weeks. Baseline values of
PANSS-FSNS, individual PANSS items, personal and social perfor-
mance (PSP), and clinical global impression of severity (CGI-S) were
analyzed based on the data gained from 11 European participating
countries.
Results Average PANSS-FSNS of patients was 27.6 ±2.48, reflect-
ing severe negative symptoms. Patients were moderately ill (CGI-S
4.2 ± 0.75), with marked difficulties (PSP 48.4 ±10.78) predomi-
nantly in social functioning. The investigated patient population
was fairly homogeneous as shown by small variability in all three
scores. Moreover, baseline values in the 11 countries presented low
variability while number of enrolled patients per country showed
high variance (n = 7–118). Narrative description of symptoms and
individual PANSS items rated as most severe and prominent were
in high correlation.
Conclusion Post hoc evaluation of this predominant negative
symptom study showed that, this patient population can be identi-
fied reliably by psychiatrist. Additional training on the judgment
of personal and social relationships can increase the diagnostic
accuracy.
Disclosure of interest Employee of Gedeon Richter Plc.
EW0482
Day-to-day and social functioning of
patients with negative symptoms of
schizophrenia: Post-hoc analyses of a
phase 3 clinical trial with cariprazine
monotherapy and risperidone
Á. Barabássy∗, I. Laszlovszky , B. Szatmári , E. Szalai , J. Harsányi ,
G. Németh
Gedeon Richter Plc, Medical Division, Budapest, Hungary
∗ Corresponding author.
Introduction Negative symptoms have substantial impact on
day-to-day functioning of patients with schizophrenia affecting
their ability to perform activities of daily living and to maintain
personal relationships.
Objective To present post hoc data on day-to-day and social func-
tioning of patients with predominant negative symptom (PNS) of
schizophrenia, treated with cariprazine versus risperidone.
Methods Data from 26 weeks, phase 3, randomized, double-
blind, active-controlled study in PNS patients were analyzed
(EudraCT 2012-005485-36). Subjects with PNS (PANSS factor score
for negative symptoms ≥24) were randomized to cariprazine
4.5mg/d or risperidone 4mg/d. Change from baseline to end of
treatment on the personal and social performance scale (PSP) and
PANSS prosocial subscale (P3, P6, N2, N4, N7, G16) was analyzed.
Results Significantly greater improvements were seen with
cariprazine compared to risperidone in the change frombaseline to
end of treatment on the PSP (LSMD + 4.632 [2.71, 6.56]; P < 0.001)
from week 10 onwards (effect size 0.48); in the PSP subdomains of
self-care (LSMD −0.2 [−0.3; −0.1]; P = 0.004), personal and social
relationships (LSMD −0.2 [−0.4;−0.1]; P < 0.001) and socially use-
ful activities (LSMD −0.4 [−0.5; −0.2]; P < 0.001); in the number
of patients who improved at least 10 points on the PSP (OR 2.1;
P = 0.001) or shifted to a higher category (OR 2.2; P = 0.001); and on
the PANSS prosocial subscale (LSMD −0.8 [−1.41, −0.16]; P = 0.014).
Conclusion Post hoc evaluation of this study showed that
cariprazine treatment is associated with a clinically relevant
improvement in patient functioning and social competence com-
pared to risperidone.
Disclosure of interest Employee of Gedeon Richter Plc.
EW0483
The relationship between negative
symptoms and cognitive functioning
in patients with an at risk mental
state for psychosis
L. Leanza∗, L. Egloff , E. Studerus , C. Andreou , U. Heitz , K. Beck ,
S. Menghini-Müller , S. Ittig , A. Riecher-Rössler
University of Basel Psychiatric Hospital, Center for Gender Research
and Early Detection, Basel, Switzerland
∗ Corresponding author.
Introduction Negative symptoms and cognitive impairments are
both present in patientswith an at riskmental state (ARMS) for psy-
chosis and negatively affect functioning and outcome. According
to previous studies in patients with first-episode psychosis, nega-
tive symptoms are negatively associatedwith cognitive functioning
while positive symptoms do not seem to be associated. Yet, little
is known about the specific relationship of negative symptoms and
cognitive functioning in ARMS patients.
Objective To evaluate, the relationship between negative symp-
toms and cognitive functioning in ARMS patients.
Methods Data of 154 ARMS patients were collected within the
prospective Basel early detection of psychosis (FePsy) study. Neg-
ative symptoms were assessed with the SANS, positive psychotic
symptoms with the BPRS, cognitive functioning with an extensive
neuropsychological test battery. Multiple regressions were applied
and results were controlled for age and gender.
Results Regression analyses showed a significant, negative asso-
ciation between negative but not positive psychotic symptoms and
cognitive functioning, showing the strongest association with ver-
bal fluency (see However, results mainly did not withstand
correction for multiple testing.